
    
      OBJECTIVES:

        -  Determine whether the balance of splice form expression alters susceptibility of tumors
           in vivo to respond to anti-VEGF therapy.

      OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory
      endpoints.
    
  